search
Back to results

A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients

Primary Purpose

Asthma

Status
Completed
Phase
Phase 3
Locations
Taiwan
Study Type
Interventional
Intervention
Meptin swinghaler
Berotec
Sponsored by
Taiwan Otsuka Pharm. Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or females outpatients aged ≥18 years old with uncontrolled or partly controlled asthma; Stability was assessed during the past 14 days the patients remained in the same severity class by 2006 GINA guideline (uncontrolled, partly controlled) and had no acute exacerbations by investigator judgment;
  • Pulmonary function test: Improvement ≥12% reversibility in FEV1 or FVC following administration of an inhaled β2-agonist before the study or ; Positive result of Brocho-provocation test;

Exclusion Criteria:

  • Hypersensitivity to β2-agonist or lactose;
  • Hospitalization due to asthma during the previous 3 months;
  • Respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks;
  • Oral or systemic corticosteroids in the previous 4 weeks;
  • Inadequately controlled hyperthyroidism;
  • Subjects with any clinically significant disorder of the cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or immunologic system or respiratory disease other than asthma(e.g. COPD), or any other disorder which may interfere wth the study evaluations or affect subject safety;
  • Patients receive an investigational drug within 30 days prior to admission to the study;
  • Patients with significant alcohol, drug or medication abuse as judged by the investigator;
  • Females who are pregnant or breast-feeding; (exception: Females of child-bearing age might be included, if in the opinion of the investigator, they are using adequate contraceptive precautions);
  • Subjects who are heavy smoker (more than 10 packs year) or who are smoking within previous 6 months.

Sites / Locations

  • Chang Cung Memorial Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Meptin swinghaler

Berotec

Arm Description

Outcomes

Primary Outcome Measures

The change of Forced Expiratory Volume in 1 second (FEV1) value

Secondary Outcome Measures

The change of Peak Expiratory Flow Rate (PEFR)
The change of Forced Vital Capacity (FVC)
Device acceptance
5-point score of evaluation form to test preference on Meptin swinghaler/ Berotec device by investigator or patient

Full Information

First Posted
March 15, 2010
Last Updated
January 15, 2013
Sponsor
Taiwan Otsuka Pharm. Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT01095016
Brief Title
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
Official Title
An Open-label, Randomized, Cross-over, Active-controlled Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
October 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Taiwan Otsuka Pharm. Co., Ltd

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using Meptin® Swinghaler and Berotec N® Metered Aerosol in stable asthma patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Meptin swinghaler
Arm Type
Experimental
Arm Title
Berotec
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Meptin swinghaler
Intervention Description
Dose: 10ug/puff, 2 puffs daily Frequency: QD (total 20ug/day) Treatment duration: 2 days
Intervention Type
Drug
Intervention Name(s)
Berotec
Intervention Description
Dose: 100ug/puff, 2 puffs daily Frequency: QD (total 200ug/day) Treatment duration: 2 days
Primary Outcome Measure Information:
Title
The change of Forced Expiratory Volume in 1 second (FEV1) value
Time Frame
12 months
Secondary Outcome Measure Information:
Title
The change of Peak Expiratory Flow Rate (PEFR)
Time Frame
12 months
Title
The change of Forced Vital Capacity (FVC)
Time Frame
12 months
Title
Device acceptance
Description
5-point score of evaluation form to test preference on Meptin swinghaler/ Berotec device by investigator or patient
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or females outpatients aged ≥18 years old with uncontrolled or partly controlled asthma; Stability was assessed during the past 14 days the patients remained in the same severity class by 2006 GINA guideline (uncontrolled, partly controlled) and had no acute exacerbations by investigator judgment; Pulmonary function test: Improvement ≥12% reversibility in FEV1 or FVC following administration of an inhaled β2-agonist before the study or ; Positive result of Brocho-provocation test; Exclusion Criteria: Hypersensitivity to β2-agonist or lactose; Hospitalization due to asthma during the previous 3 months; Respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks; Oral or systemic corticosteroids in the previous 4 weeks; Inadequately controlled hyperthyroidism; Subjects with any clinically significant disorder of the cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or immunologic system or respiratory disease other than asthma(e.g. COPD), or any other disorder which may interfere wth the study evaluations or affect subject safety; Patients receive an investigational drug within 30 days prior to admission to the study; Patients with significant alcohol, drug or medication abuse as judged by the investigator; Females who are pregnant or breast-feeding; (exception: Females of child-bearing age might be included, if in the opinion of the investigator, they are using adequate contraceptive precautions); Subjects who are heavy smoker (more than 10 packs year) or who are smoking within previous 6 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yu-Hsiu Chung, MD
Organizational Affiliation
Chang Cung Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chang Cung Memorial Hospital
City
Taipei
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients

We'll reach out to this number within 24 hrs